Oceana Group Limited (OCGPF)

OTCMKTS · Delayed Price · Currency is USD
3.000
+0.432 (16.82%)
At close: Dec 30, 2025
Market Cap418.02M -3.6%
Revenue (ttm)578.64M -0.7%
Net Income39.02M -39.1%
EPS0.33 -38.8%
Shares Outn/a
PE Ratio10.71
Forward PE8.11
Dividendn/a
Ex-Dividend Daten/a
Volume500
Average Volume620
Open3.000
Previous Close2.568
Day's Range3.000 - 3.000
52-Week Range2.568 - 3.600
Beta0.34
RSI41.12
Earnings DateMar 10, 2026

About Oceana Group

Oceana Group Limited operates as a fishing and food processing company in South Africa, Namibia, rest of Africa, North America, Europe, the Far East, and internationally. It engages in catching, processing, and procuring various marine species, including pilchard, anchovy, redeye herring, Gulf menhaden, lobster, squid, horse mackerel, and hake, as well as processing of meat, chicken, and vegetable products. The company also markets and sells canned fish, fishmeal, and fish oil products, as well as frozen and fresh products. Oceana Group Limited... [Read more]

Founded 1918
Country South Africa
Stock Exchange OTCMKTS
Ticker Symbol OCGPF
Full Company Profile

Financial Performance

In fiscal year 2025, Oceana Group's revenue was 10.00 billion, a decrease of -0.66% compared to the previous year's 10.06 billion. Earnings were 674.00 million, a decrease of -39.11%.

Financial numbers in ZAR Financial Statements

News

Oceana Group Limited (OCGPF) Q4 2025 Earnings Call Transcript

Oceana Group Limited (OTCPK:OCGPF) Q4 2025 Earnings Call November 23, 2025 7:00 PM EST Company Participants Neville Brink - CEO & Executive Director Zafar Mahomed - CFO & Executive Director Presentati...

2 months ago - Seeking Alpha

Oceana Group Limited 2025 Q4 - Results - Earnings Call Presentation

2025-11-26. The following slide deck was published by Oceana Group Limited in conjunction with their 2025 Q4 earnings call.

2 months ago - Seeking Alpha

Oceana Group Limited - Special Call

5 months ago - Seeking Alpha

Press Release: Sanofi's amlitelimab met all primary and key secondary endpoints in the COAST 1 phase 3 study in adults and adolescents with atopic dermatitis

Sanofi's amlitelimab met all primary and key secondary endpoints in the COAST 1 phase 3 study in adults and adolescents with atopic dermatitis Amlitelimab, dosed every four weeks or every 12 weeks, de...

5 months ago - Benzinga

Oceana Group Limited to Present at the Small Cap Growth Virtual Investor Conference December 5th

Company invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.com Company invites individual and institutional investors, as ...

1 year ago - GlobeNewsWire